Avifavir has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.
RDIF and ChemRar to Deliver 60,000 Courses of the First COVID-19 Drug Registered in Russia,
Avifavir, to the Country’s Hospitals in June –
Global landmark in the successful treatment of COVID-19
Avifavir is the first direct-acting antiviral drug registered in Russia that has proven effective against COVID-19 in clinical trials
Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19
MOSCOW, June 1, 2020 /PRNewswire/ —
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group
will deliver 60,000 courses of Avifavir to Russian hospitals in June.
Avifavir is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.
Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation.
Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
In early June,
the first batches of Avifavir will be sent to Russia’s Federal Service for Surveillance in Healthcare (Roszdravnadzor) for approval for use.
Deliveries of the first batches of the drug to Russian hospitals are expected on June 11, 2020.
The high quality of Avifavir
is due to more stringent requirements for its active pharmaceutical ingredient, compared with the requirements for active pharmaceutical ingredients in international markets.
P&T Community
Russia to roll out its first approved Covid-19 drug next week
Russian hospitals can begin giving the antiviral drug,
which is registered under the name Avifavir, to patients from June 11,
the head of Russia’s RDIF sovereign wealth fund told Reuters in an interview.
He said the company behind the drug would manufacture enough to treat around 60,000 people a month.
world news Hindustan Times